Copyright © 1990 by the European Society of Cardiology.
© 1990 The European Society of Cardiology
The role of perfusion data
University of California, San Francisco, School of Medicine California, U.S.A.
Correspondence: Elliot Rapaport MD, Department of Medicine, University of California, San Francisco, School of Medicine, and Cardiology Division, Medical Service, San Francisco General Hospital, San Francisco, California, USA
The use of a thrombolytic agent, whether streptokinase, t-PA, or APSAC, clearly has a profound benefit in reducing mortality when used in the early hours following an acute myocardial infarction. The reasons for this benefit in mortality are unexplained by early patency rates alone. The choice of one thrombolytic agent over another ultimately must rest on the results of randomized studies directly comparing them, with mortality as the end-point. Hopefully, GISSI-II and ISIS-III will give us these answers.
Key Words: Thrombolysis streptokinase t-PA APSAC acute myocardial infarction recanalization reperfusion patency